Nexsen (ASX:NXN) announced a critical breakthrough in its international expansion strategy, completing a pre-submission meeting with the US Food and Drug Administration.
The milestone, conducted under the FDA’s Q-Submission program, provides a formalised and lower-risk pathway for the company's lead diagnostic product, StrepSure, as it heads toward US market authorisation.
By securing positive feedback on its proposed regulatory strategy and clinical validation approach, Nexsen has effectively de-risked the approval process for what is set to be its first product in the American maternal health sector.
The US market represents a substantial commercial opportunity for the Australian biotech firm.
StrepSure is designed to integrate into standard prenatal care for Group B Streptococcus screening, offering a repeatable and scalable testing solution for a large annual birth cohort.
Beyond the immediate impact of StrepSure, the FDA's alignment validates Nexsen’s broader point-of-care platform, which aims to replace traditional lab-based testing for various time-critical conditions.
Managing Director Mark Muzzin emphasised that the feedback provides the team with the necessary clarity to streamline future submissions within their diagnostic pipeline.
As Nexsen advances its regulatory and commercial workstreams, the company remains focused on transitioning from development to a planned commercial rollout.